(Q28171087)

1

0 references

Guenther Gastl

2

0 references

Wieslaw-Wiktor Jedrzejczak

3

0 references

Robert Pytlik

4

0 references

Werner Lin

5

0 references

Ernst Schlögl

Long-term use of anagrelide in young patients with essential thrombocythemia

6

0 references

language of work or name

English

0 references

publication date

15 November 2004

0 references

published in

Cancer

0 references

volume

101

0 references

issue

10

0 references

page(s)

2239-46

0 references

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20646

Efficacy and safety of low-dose aspirin in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20646

Studies of platelet volume, chemistry and function in patients with essential thrombocythaemia treated with Anagrelide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20646

Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20646

Should a platelet limit of 600 x 109/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20646

Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20646

7 January 2021

Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20646

7 January 2021

Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20646

7 January 2021

Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20646

7 January 2021

Controlled and uncontrolled thrombocytosis. Its clinical role in essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20646

7 January 2021

Clinical manifestations of essential thrombocythemia in young adults

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20646

7 January 2021

Long-term interferon therapy for thrombocytosis in myeloproliferative diseases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20646

7 January 2021

Interferon in essential thrombocythaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20646

7 January 2021

The effect of interferon alpha on myeloproliferation and vascular complications in polycythemia vera.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20646

7 January 2021

Anagrelide: A New Drug for Treating Thrombocytosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20646

7 January 2021

Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Anagrelide Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20646

7 January 2021

Anagrelide, a novel platelet lowering option in essential thrombocythaemia: treatment experience in 48 patients in Germany.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20646

7 January 2021

Efficacy, safety and tolerability of anagrelide in the treatment of essential thrombocythaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20646

7 January 2021

Effectiveness of anagrelide in the treatment of symptomatic patients with essential thrombocythemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20646

7 January 2021

A long-term retrospective study of young women with essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20646

7 January 2021

Myeloproliferative disorders: complications, survival and causes of death

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20646

7 January 2021

Anagrelide: a novel agent for the treatment of myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20646

7 January 2021

Anagrelide, a selective thrombocytopenic agent

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20646

7 January 2021